The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients

Psychiatric Genetics

Volumn 18, Issue 4, 2008, Pages 184-190

  Smits, Kim M ^a   Smits, Luc J M ^a   Peeters, Frenk P M L ^a   Schouten, Jan S A G ^a   Janssen, Rob G J H ^a   Smeets, Hubert J M ^a   Van Os, Jim ^a   Prins, Martin H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Depression; Pharmacogenetics; Polymorphisms; Selective serotonin reuptake inhibitors; Serotonin transporter; Treatment outcome

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SLC6A4 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ALLELE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; ORAL BIOPSY; PHARMACOGENETICS; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME; CONFIDENCE INTERVAL; DEPRESSION; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; REGRESSION ANALYSIS; RISK;

ADULT; ALLELES; CONFIDENCE INTERVALS; DEPRESSION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 50349096409     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/YPG.0b013e3283050aca     Document Type: Article

References (33)

1. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L (2003). 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 23:563-567.
2. Baca-Garcia E, Vaquero C, Diaz-Sastre C, Saiz-Ruiz J, Fernandez-Piqueras J, de Leon J, et al. (2002). A gender-specific association between the serotonin transporter gene and suicide attempts. Neuropsychopharmacology 26:692-695.
3. Cardon LR, Palmer LJ (2003). Population stratification and spurious allelicassociation. Lancet 361:598-604.
4. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386-389.
5. Du L, Bakish D, Hrdina PD (2000). Gender differences in association between serotonin transporter gene polymorphism and personality traits. Psychiatr Genet 10:159-164.
6. Ito K, Yoshida K, Sato K, Takahashi H, Kamata M, Higuchi H, et al. (2002). A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 111:235.
7. Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B (2005). The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 62:529-535.
8. Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA (2005). Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol 25:318-324.
9. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, et al. (2000). Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11:215-219.
10. Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT (2005). Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neuropsychiatr Genet 133:110-115.
11. Lesch KP (2001a). Serotonergic gene expression and depression: implications for developing novel antidepressants. J Affect Disord 62:57-76.
12. Lesch KP (2001b). Variation of serotonergic gene expression: neurodevelopment and the complexity of response to psychopharmacologic drugs. Eur Neuropsychopharmacol 11:457-474.
13. Lotrich FE, Pollock BG (2004). Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet 14:121-129.
14. Lotrich FE, Pollock BG, Ferrell RE (2001). Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. Am J Pharmacogenomics 1:153-164.
15. Marazziti D, Rossi A, Palego L, Barsanti A, Carrai M, Giannaccini G, et al. (1998). Effect of aging and sex on the [3H]-paroxetine binding to human platelets. J Affect Disord 50:11-15.
16. Metsemakers JF, Hoppener P, Knottnerus JA, Kocken RJ, Limonard CB (1992). Computerized health information in The Netherlands: a registration network of family practices. Br J Gen Pract 42:102-106.
17. Miettinen O (1985). Theoretical epidemiology: principles of occurrence research in medicine. New York: Wiley.
18. Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM, et al. (1996). Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347:731-733.
19. Park JW, Kim JS, Lee HK, Kim YI, Lee KS (2004). Serotonin transporter polymorphism and harm avoidance personality in chronic tension-type headache. Headache 44:1005-1009.
20. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. (2000). Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587-590.
21. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Mac Hobby H, et al. (2002). Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 51:723-732.
22. Shear K, Roose SP, Lenze EJ, Alexopoulos GS (2005). Depression in the elderly: the unique features related to diagnosis and treatment. CNS Spectr 10:1-13.
23. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998). Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508-511.
24. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH (2004). Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 9:433-441.
25. Steimer W, Muller B, Leucht S, Kissling W (2001). Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 308:33-41.
26. Thase ME, Entsuah R, Cantillon M, Kornstein SG (2005). Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 14:609-616.
27. Thiels C, Linden M, Grieger F, Leonard J (2005). Gender differences in routine treatment of depressed outpatients with the selective serotonin reuptake inhibitor sertraline. Int Clin Psychopharmacol 20:1-7.
28. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28-40.
29. Wacholder S, Rothman N, Caporaso N (2000). Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 92:1151-1158.
30. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, et al. (2002). Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 26:383-386.
31. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ (2002). Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7:1115-1119.
32. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000). Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20:105-107.
33. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, et al. (2001). Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50:323-330.